Janssen Vaccines & Prevention B.v.

Johannes P M Langedijk

Gabriel Pascual

Robert Anthony Williamson

Jehangir Wadia

Angelique Van 't Wout

Lucy Rutten

Anders Krarup

Daphné Truan

Nika Mindy Strokappe

Human immunodeficiency virus (HIV) envelope proteins having mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins have certain amino acid substitutions at specified positions in the envelope protein sequence. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield as compared to an HIV envelope protein that does not have one or more of the indicated amino acid substitutions. Also provided are nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, nucleic acid, and vectors.

Trimer stabilizing HIV envelope protein mutations

This disclosure provides stable pre-fusion respiratory syncytial virus (RSV) F polypeptides, immunogenic compositions comprising the polypeptides, and uses thereof for the prevention and/or treatment of RSV infection.

Stabilized soluble pre-fusion RSV F polypeptides

The disclosure relates to isolated antibodies and antigen-binding fragments that bind to the G protein of RSV and which are capable of neutralizing RSV A and B subtypes, and the use thereof in the diagnosis, prophylaxis, and/or treatment of RSV infections.

Human antibodies binding to RSV G protein

The disclosure provides isolated antibodies and antigen-binding fragments that bind to the G protein of RSV and which are capable of neutralizing RSV.

Growing community of inventors

Amsterdam, Netherlands

Johannes P M Langedijk